G01N33/5044

Composition for treating or diagnosing osteoarthritis targeting ACVR2B

The present disclosure relates to a composition for treating or diagnosing osteoarthritis targeting activin A receptor type 2B (ACVR2B). More specifically, the present disclosure provides ACVR2B as a biomarker for diagnosing osteoarthritis because it was found that expression and activity of ACVR2B were increased at an early stage of osteoarthritis, expression of Mmp3, Mmp13, and Cox2 that induce destruction of cartilage was increased thereby, and expression of the genes was suppressed by inhibition of ACVR2B expression. In addition, since it was found that osteoarthritis was alleviated by suppressing the expression of ACVR2B, the present disclosure provides an ACVR2B expression or activity inhibitor as a therapeutic agent for osteoarthritis.

Methods of identifying and treating patients with HIF-2 inhibitor resistance

The present disclosure provides methods of identifying patients who have partial or total resistance to HIF-2 inhibitors or who develop partial or total resistance to HIF-2 inhibitors after treatment and providing suitable treatment to these patients.

Method of preparing an artificial tooth primordium in vitro and artificial tooth primordium derived therefrom

The present invention is directed to a method of preparing an artificial tooth primordium in vitro, comprising the steps: a) providing isolated mesenchymal dental pulp cells; and b) culturing the mesenchymal dental pulp cells under non-adherent conditions to form a cell aggregate representing an artificial tooth primordium; as well as to an artificial tooth primordium derived therefrom.

METHOD OF DETERMINING SKIN AGING
20230041417 · 2023-02-09 ·

The present invention provides methods of diagnosing and treating fast aging skin, especially in young subjects, by measuring and/or adjusting a property selected from cell proliferation rate, NFKB1 gene expression, CDKN1A gene expression, CDKN2A gene expression, CEBPB gene expression, and combinations thereof.

CULTURE MEDIUM FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA EPITHELIAL CELLS, CULTURE METHOD, AND APPLICATION THEREOF

Provided are a primary cell culture medium that contains a combination of an MST1/2 kinase inhibitor and a ROCK kinase inhibitor and is used for culturing primary esophageal squamous cell carcinoma epithelial cells, and a culture method using the primay cell culture medium. In the culture method, the primary cell culture medium is used to culture primay cells on a culture vessel coated with an extracellular matrix glue, so that the primary cells prolilferate rapidly. A cell model obtained by using the primary cell culture medium and the primary cell culture method of the present invention can be used for the efficacy evaluation and screening of drugs.

MATERIALS AND METHODS FOR INFLAMMATORY MOLECULAR MARKERS
20230003719 · 2023-01-05 ·

A method of determining a pharmacodynamics or pharmacokinetic effect of an inhibitor of IL 1α comprising providing a sample from a subject; administering the inhibitor of IL 1α to the sample; measuring levels of one or more biomarkers in the sample; and determining the pharmacodynamic or the pharmacokinetic effect of the inhibitor of IL 1α based on the levels of the one or more biomarkers.

Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits

The invention provides a method of treatment comprising reducing therapy-induced adverse effects (TIAE), including chemotherapy-induced adverse effects (CIAE), such as chemotherapy-induced peripheral neuropathy (CIPN) and/or chemotherapy-induced cardiovascular adverse effects (CICAE) in a subject being treated with a CIAE-inducing anti-cancer active ingredient by co-administering to the subject a pharmaceutically effective amount of a NCS-1-protective composition. Related pharmaceutical compositions, diagnostics and screening techniques are also provided.

Screening method for laminin 511 production promoting agent, basal epidermal layer stabilizing agent, and/or epidermal stem cells reduction inhibiting or proliferation promoting agent
11564959 · 2023-01-31 · ·

Provided is a screening method for a laminin 511 expression promoter, which takes the expression of laminin 511 as an indicator. Also provided is an agent for improving skin barrier function, elasticity, hydration and inflammation. This agent includes at least one extract selected from among a group consisting of brown algae, red algae and green algae.

Identifying status of male fertility by determining sperm capacitation

This disclosure provides a method for determining male fertility status. The method comprises determining G.sub.M1 distribution patterns following induced sperm capacitation, identifying the frequency of distribution of various patterns, and determining if the frequency distribution of certain G.sub.M1 patterns in response to induced capacitation is altered. Based on the change in the frequency distribution patterns of certain patterns in response to induced capacitation, alone or in combination with other sperm attributes, male fertility status can be identified.

SCREENING METHOD FOR LAMININ 511 PRODUCTION PROMOTING AGENT, BASAL EPIDERMAL LAYER STABILIZING AGENT, AND/OR EPIDERMAL STEM CELLS REDUCTION INHIBITING OR PROLIFERATION PROMOTING AGENT
20230210928 · 2023-07-06 · ·

The purpose of this invention is to provide a method with which it is easy to perform screening for an agent that proliferates or an agent that minimizes the reduction in MCSP-positive basal epidermal stem cells. Provided is a screening method for a laminin 511 expression promoter, which takes the expression of laminin 511 as an indicator. Also provided is an agent for improving skin barrier function, elasticity, hydration and inflammation, said agent including at least one extract selected from among a group consisting of brown algae, red algae and green algae.